Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SIK1 | P57059 | 1/20 | 0.31 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.31 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21875055 | 0.82 | KMT2A (0.45) | KMT2AMAPTPKMATMALDH1A1 | |
| SCHEMBL5234643 | 0.72 | PDK1 (0.42) | KMT2AMAPTPKMATMALDH1A1 | |
| SCHEMBL3029826 | 0.71 | GAA (0.40) | KMT2AGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL11735902 | 0.69 | GAA (0.67) | KMT2AGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL13971212 | 0.69 | — | — | |
| SCHEMBL10855357 | 0.68 | DRD2 (0.41) | KMT2AMAPTPKMATMALDH1A1 | |
| SCHEMBL3043860 | 0.68 | RAB9A (0.35) | KMT2AGAAMAPTPKMALDH1A1 | |
| Hydrochloric Acid SCHEMBL10856566 | 0.67 | PKM (0.42) | KMT2AMAPTPKMATMSIK1 | |
| SCHEMBL27925114 | 0.63 | MAPT (0.44) | KMT2AGAAMAPTATMALDH1A1 | |
| SCHEMBL1695044 | 0.63 | MAPT (0.42) | KMT2AMAPTPKMATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170872-B1 | PROCESS FOR THE PREPARATION OF THE N-(2-CHLORO-4-METHYL-3-THIENYL)-1H- BENZIMIDAZOL-2-AMINE HYDROCHLORIDE AND INTERMEDIATES THEREOF | SANOFI AVENTIS US LLC (US) | 2010-09-01 | — | — | EP | claimed |
| US-20100174088-A1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL AS SODIUM/PROTON EXCHANGER TYPE 3 INHIBITORS | SANOFI-AVENTIS U.S. LLC (US) | 2010-07-08 | — | — | US | claimed |
| EP-2170872-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF | Sanofi-Aventis U.S. LLC (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2009006066-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF | SANOFI-AVENTIS U.S. LLC (US) | 2009-01-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174088-A1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL AS SODIUM/PROTON EXCHANGER TYPE 3 INHIBITORS | SLC9A3, NHERF1, SLC9A5 | KMT2A 1001/4885GAA 1214/4885MAPT 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.